Christophe LE TERRIER

University of Fribourg

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

ORCID

Google Scholar

Articles (18)

Impact of extended-spectrum chromosomal AmpC (ESAC) of Escherichia coli on susceptibility to cefiderocol

Article Link

Year:

2024

Impact of intensive prone position therapy on outcomes in intubated patients with ARDS related to COVID-19

Article Link

Year:

2024

Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa

Article Link

Year:

2024

Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases

Article Link

Year:

2024

Pulmonary embolism impacts clinical outcomes of intubated patients with acute respiratory distress syndrome related to COVID-19

Article Link

Year:

2024

Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor taniborbactam against metallo-β-lactamases

Article Link

Year:

2024

Structural basis of metallo-β-lactamase resistance to taniborbactam

Article Link

Year:

2024

Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?

Article Link

Year:

2024

Association of Trace Element Levels with Outcomes in Critically Ill COVID-19 Patients

Article Link

Year:

2023

Anaesthetic and peri-operative management for thrombectomy procedures in stroke patients

Article Link

Year:

2023

Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli

Article Link

Year:

2023

Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern

Article Link

Year:

2023

No waiting lying in a corridor: a quality improvement initiative in an emergency department

Article Link

Year:

2023

Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa

Article Link

Year:

2023

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates

Article Link

Year:

2023

In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases

Article Link

Year:

2023

Protocol Title: Effect of POsitive therapeutic communication on PAIN and anxiety during arterial blood gas standardized procedures in the emergency department compared with traditional communication: a monocentric randomized controlled trial (Preprint)

Article Link

Year:

2022

Impact of nutritional therapy during the first wave of the COVID-19 pandemic in intensive care patients: A retrospective observational study

Article Link

Year:

2022

Collaborators (9)

Sabrina Pagano

Geneva University Hospitals (HUG)

SWITZERLAND

Silvia Stringhini

Associate Professor

The University of British Columbia

CANADA

Patrice Nordmann

University of Fribourg

SWITZERLAND

Tinh‐Hai Collet

SWITZERLAND

Mustafa Sadek

University of Fribourg

SWITZERLAND

Aurelien Thomas

Professor-Head of Unit

University of Lausanne

SWITZERLAND

Katia Iglesias

Full Professor HES

University of Applied Sciences and Arts Northwestern Switzerland

SWITZERLAND

Hannah Wozniak

University Hospital of Geneva

SWITZERLAND

Laurent Poirel

University of Fribourg

SWITZERLAND

Christophe LE TERRIER

Research Interests

Explore related searches

Contact this professor

Articles (18)

Impact of extended-spectrum chromosomal AmpC (ESAC) of Escherichia coli on susceptibility to cefiderocol

Impact of intensive prone position therapy on outcomes in intubated patients with ARDS related to COVID-19

Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa

Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases

Pulmonary embolism impacts clinical outcomes of intubated patients with acute respiratory distress syndrome related to COVID-19

Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor taniborbactam against metallo-β-lactamases

Structural basis of metallo-β-lactamase resistance to taniborbactam

Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?

Association of Trace Element Levels with Outcomes in Critically Ill COVID-19 Patients

Anaesthetic and peri-operative management for thrombectomy procedures in stroke patients

Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli

Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern

No waiting lying in a corridor: a quality improvement initiative in an emergency department

Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates

In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases

Protocol Title: Effect of POsitive therapeutic communication on PAIN and anxiety during arterial blood gas standardized procedures in the emergency department compared with traditional communication: a monocentric randomized controlled trial (Preprint)

Impact of nutritional therapy during the first wave of the COVID-19 pandemic in intensive care patients: A retrospective observational study

Collaborators (9)

Sabrina Pagano

Silvia Stringhini

Patrice Nordmann

Tinh‐Hai Collet

Mustafa Sadek

Aurelien Thomas

Katia Iglesias

Hannah Wozniak

Laurent Poirel

How do I reach out?

Meet Kite AI